The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index; 61 of the 99 sources its claims cite were checked for support.
Credibility assessment of in silico clinical trials for medical devices
Open accessAbstract
In silico clinical trials (ISCTs) are an emerging method in modeling and simulation where medical interventions are evaluated using computational models of patients. ISCTs have the potential to provide cost-effective, time-efficient, and ethically favorable alternatives for evaluating the safety and effectiveness of medical devices. However, ensuring the credibility of ISCT results is a significant challenge. This paper aims to identify unique considerations for assessing the credibility of ISCTs and proposes an ISCT credibility assessment workflow based on recently published model assessment frameworks. First, we review various ISCTs described in the literature, carefully selected to showcase the range of methodological options available. These studies cover a wide variety of devices, reasons for conducting ISCTs, patient model generation approaches including subject-specific versus ‘synthetic’ virtual patients, complexity levels of devices and patient models, incorporation of clinician or clinical outcome models, and methods for integrating ISCT results with real-world clinical trials. We next discuss how verification, validation, and uncertainty quantification apply to ISCTs, considering the range of ISCT approaches identified. Based on our analysis, we then present a hierarchical workflow for assessing ISCT credibility, using a general credibility assessment framework recently published by the FDA’s Center for Devices and Radiological Health. Overall, this work aims to promote standardization in ISCTs and contribute to the wider adoption and acceptance of ISCTs as a reliable tool for evaluating medical devices.
Overview
CoChat Summary
TL;DR
This paper reviews eight medical-device in silico clinical trials (ISCTs) and proposes a hierarchical workflow for assessing ISCT credibility based on FDA guidance and ASME V&V40. It argues that ISCT credibility requires sub-model-level verification, validation, and uncertainty quantification, plus population-level validation of the virtual cohort.
Key findings
- ISCTs are composed of multiple sub-models—baseline patient model, device model, virtual cohort, and optionally clinical outcome, clinician, emulator, and other system models—so credibility assessment should be hierarchical rather than only top-level.
- The reviewed examples span subject-specific, synthetic, and mixed virtual cohorts: MR-induced heating used 15 subject-specific models from 12 subjects; VICTRE used 2,986 synthetic patients; FD-PASS used 164 virtual patients from 82 anatomies; the artificial pancreas example used 300 synthetic patients; whole-heart CRT models used 24 subject-specific models altered to heart failure; automata-based ICD models used >11,000 virtual patients; and Micra involved 50 million simulations total.
- Validation can occur at sub-model level (device, patient, coupled device-patient, clinical outcome, clinician) and at cohort level, either individual-level with paired data or population-level without paired data; population-level validation alone risks “right answer for the wrong reason.”
- The proposed workflow aligns with FDA credibility categories and adds credibility factors/gradations for population-level validation of the virtual cohort, including clinical dataset size, subject range, output comparison rigor, and agreement.
Methods
- Narrative review of eight selected ISCTs for medical devices, chosen to showcase methodological range rather than to comprehensively survey all ISCTs.
- Qualitative synthesis of how verification, validation, and uncertainty quantification apply to ISCTs, including sub-model and cohort validation strategies.
- Proposal of a hierarchical ISCT credibility assessment workflow based on FDA guidance “Assessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions” and ASME V&V40-2018, illustrated with a hypothetical whole-heart/pacemaker-lead ISCT.
Limitations
- The paper states the workflow may be perceived as overly burdensome, may require case-specific adjustments, and such adjustments could introduce subjectivity.
- The paper states its scope is first-principles models; data-driven models are not harmonized with first-principles credibility assessment, and ISCT execution is outside scope.
- The paper states there is no widely accepted community definition of an ISCT, and the literature review is not comprehensive; the proposed workflow also assumes specific features such as a physics-based device model, first-principles patient model, no emulator or explicit clinician model, synthetic cohort, and no Bayesian ISCT/CT integration.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
45 Valid · 9 Not valid · 24 Not checked · 105 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The flow diverter performance assessment (FD-PASS) study [16] was an in silico clinical trial that predicted post-treatment flow reduction in 164 virtual patients using computational fluid dynamics (CFD).”
§ Credibility assessment of in silico clinical trials for medical devices > 2. In silico clinical trials for medical devices > 2.3. Example ISCTs for medical devices
What the sources say
- Supportedcites [16] A Sarrami-Foroushani, 2021, In-silico trial of intracranial flow diverters replicates and expands insights from conventional clinical trials, Nature communications source
The Introduction’s Fig. 1 workflow describes 82 virtual anatomies modeled under normotensive and hypertensive conditions (N = 164), with the 3-D Navier–Stokes equations solved to measure post-treatment aneurysm mean velocity reduction. The Introduction also identifies FD-PASS as an in-silico trial with post-treatment velocity reduction as its primary endpoint. (LLM, conf=0.93)
plainstates a causen = 164- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Studies where multiple modeling groups attempt to solve the same pre-specified problem have been useful in various fields for code verification and, more generally, for scientific reproducibility [48–50].”
§ Credibility assessment of in silico clinical trials for medical devices > 3. Verification, validation and uncertainty quantification for ISCTs > 3.1. Verification
What the sources say
- Partly supportedcites [48] K Valen-Sendstad, 2018, Real-world variability in the prediction of intracranial aneurysm wall shear stress: the 2015 international aneurysm CFD challenge, Cardiovascular engineering and technology sourceExperimental — accuracy not yet measured
The Methods (Response to the Challenge; page not provided) describe 26 modeling teams submitting CFD results, and the Conclusions report variability that impedes combining results across groups. This supports the study as an example of a multi-group reproducibility challenge, but our copy does not establish that such studies have been useful across various fields or for code verification. (LLM, conf=0.84)
- Supportedcites [49] SA Niederer, 2011, Verification of cardiac tissue electrophysiology simulators using an N-version benchmark, Phil. Trans. R. Soc. A source
Section 2 describes multi-code comparisons of common problems in earth science, astronomy, meteorology and mantle simulation as code-verification strategies. It says the shared-benchmark approach also demonstrates that a benchmark is reproducible; the Benchmark utility section describes this study as confirming the reproducibility of multi-scale simulations. (LLM, conf=0.91)
- Partly supportedcites [50] I Sechopoulos, 2015, Monte Carlo reference data sets for imaging research: Executive summary of the report of AAPM Research Committee Task Group 195, Medical physics sourceExperimental — accuracy not yet measured
The Abstract and Section 2.A describe four Monte Carlo packages applied to the same specified imaging simulations, and the Discussion explains how comparing their results helps benchmark and validate simulation codes. The paper supports that example, but does not establish usefulness across various fields or for scientific reproducibility more generally. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The results of the ISCT compared favorably with the results of an existing clinical trial that was used as a reference”
§ Credibility assessment of in silico clinical trials for medical devices > 2. In silico clinical trials for medical devices > 2.3. Example ISCTs for medical devices
What the sources say
- Supportedcites [32] A Badano, 2018, Evaluation of digital breast tomosynthesis as replacement of full-field digital mammography using an in silico imaging trial, JAMA network open source
The Results state that VICTRE’s differential performance was consistent with the comparative trial’s aggregate results and its stronger performance for detecting masses than microcalcifications. The Discussion likewise says the overall results were consistent with the comparative trial, supporting the claim that the in silico trial compared favorably with its clinical reference. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“the Virtual Imaging Clinical Trial for Regulatory Evaluation (VICTRE) project [32] explored the possibility of using an ISCT to compare the performance of FFDM and DBT.”
§ Credibility assessment of in silico clinical trials for medical devices > 2. In silico clinical trials for medical devices > 2.3. Example ISCTs for medical devices
What the sources say
- Supportedcites [32] A Badano, 2018, Evaluation of digital breast tomosynthesis as replacement of full-field digital mammography using an in silico imaging trial, JAMA network open source
The Discussion describes VICTRE as an in silico trial comparing digital mammography (DM) with digital breast tomosynthesis (DBT), and reports their differential performance. The paper’s title identifies the mammography modality as full-field digital mammography. Page numbers were not available in our copy. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“First, we noted that with PSMs it is common to perform calculation verification studies such as grid refinement studies using a single, assumed representative, patient.”
§ Credibility assessment of in silico clinical trials for medical devices > 3. Verification, validation and uncertainty quantification for ISCTs > 3.1. Verification
What the sources say
- Supportedcites [9] SK Galappaththige, 2022, Credibility Assessment of Patient-Specific Computational Modeling using Patient-Specific Cardiac Modeling as an Exemplar, PLOS Computational Biology source
Section 2.2 says that in cardiac patient-specific models, often either no verification is performed or a single mesh-resolution study is used to justify the resolution for all patients. This supports the claim that, when such a study is performed, it commonly uses one patient as representative of the others. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
33 more claims · 6 with their cited sources checked
Create a free account to see all 183 claims and to verify the 2 references still open.
- Probably not a substantial claim. 126
- It may state two separate claims as one. 49
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Credibility assessment of in silico clinical trials for medical devices > 2. In silico clinical trials for medical devices > 2.3. Example ISCTs for medical devices
“10K simulated trials of 5K virtual patients each, 50M simulations total”
§ Credibility assessment of in silico clinical trials for medical devices > 2. In silico clinical trials for medical devices > 2.3. Example ISCTs for medical devices
“The study involved 5,000 simulated trials, each comprised of 10,000 virtual patients, for a total of 50 million simulations.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Credibility assessment of in silico clinical trials for medical devices > 3. Verification, validation and uncertainty quantification for ISCTs > 3.2. Validation
“enabling validation of both the virtual patient in isolation and the coupled device-patient model (Fig 2d; see [56] for an example in stent-graft deployment)”
§ Credibility assessment of in silico clinical trials for medical devices > References
“56. O’Hara T, Virag L, Varro A, Rudy Y, Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Credibility assessment of in silico clinical trials for medical devices > 3. Verification, validation and uncertainty quantification for ISCTs > 3.2. Validation
“If subject-specific virtual patients are generated (whether for cohort generation approaches A, B or C in Fig 1), validation may be possible against other data collected from the same subjects–see Fig 2b.”
§ Credibility assessment of in silico clinical trials for medical devices > 3. Verification, validation and uncertainty quantification for ISCTs > 3.2. Validation
“| Validate patient model | Fig 2b | Patient model using nominal or population-averaged parameter values | Population-averaged clinical data | Cardiac modeling [56] | 4 |”
Citations
Cites
An Introduction to Statistical Learning
James, G., Witten, D., Hastie, T., & Tibshirani, R. (2013) · Springer Texts in Statistics · doi:10.1007/978-1-4614-7138-7 · Cited by 12,106
Physics-informed machine learning
Karniadakis, G. E., Kevrekidis, I. G., Lu, L., Perdikaris, P., Wang, S., & Yang, L. (2021) · Nature Reviews Physics · doi:10.1038/s42254-021-00314-5 · Cited by 8,718
Understanding bland altman analysis
Giavarina, D. (2015) · Biochemia Medica · doi:10.11613/bm.2015.015 · Cited by 4,706
Verification and Validation in Scientific Computing
Oberkampf, W. L., & Roy, C. J. (2010) · doi:10.1017/cbo9780511760396 · Cited by 1,556
Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models
Zou, K. H., O’Malley, A. J., & Mauri, L. (2007) · Circulation · doi:10.1161/circulationaha.105.594929 · Cited by 1,473
O'Hara, T., Virág, L., Varró, A., & Rudy, Y. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002061 · Cited by 1,196
The ‘Digital Twin’ to enable the vision of precision cardiology
Corral-Acero, J., Margara, F., Marciniak, M., Rodero, C., Loncaric, F., Feng, Y., Gilbert, A., Fernandes, J. F., Bukhari, H. A., Wajdan, A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa159 · Cited by 932
Self-citationExternal validation of prognostic models: what, why, how, when and where?
Ramspek, C. L., Jager, K. J., Dekker, F. W., Zoccali, C., & van Diepen, M. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa188 · Cited by 887
The UVA/PADOVA Type 1 Diabetes Simulator: New Features
Man, C. D., Micheletto, F., Lv, D., Breton, M., Kovatchev, B., & Cobelli, C. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296813514502 · Cited by 791 · cited 1×
“Another example is compartmental glucose-insulin models, which have been used to generate virtual cohorts to evaluate automated insulin pumps [38,39] (more details in Table 1).”
In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes
Kovatchev, B. P., Breton, M., Dalla Man, C., & Cobelli, C. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300106 · Cited by 760
Cited by
The future of in silico trials and digital twins in medicine
Samei, E. (2025) · PNAS Nexus · doi:10.1093/pnasnexus/pgaf123 · Cited by 39
Aycock, K. I., Battisti, T., Peterson, A., Jiang, Y. D., Kreuzer, S. M., Capelli, C., Pant, S., Pathmanathan, P., Hoganson, D. M., Levine, S. M., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1433372 · Cited by 40
Self-citationAlharthi, S. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00055-x · Cited by 43
“…a patient, organ, or biological system that integrates multidimensional, patient-specific data to support clinical decision-making (Drummond & Gonsard 2024), while ISTs refer to structured and comprehensive computational simulations conducted using or in conjunction with DTs (Table 2) (Samei 2025).”
MASLD, MASH, and the CKM Spectrum
Zannad, F. M., Khan, M. S., Bansal, N., Böhm, M., Francque, S., Girerd, N., Januzzi, J. L., Miller, V., Piché, M., Ratziu, V., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.12.015 · Cited by 40
Toward widespread use of virtual trials in medical imaging innovation and regulatory science
Abadi, E., Barufaldi, B., Lago, M. A., Badal, A., Mello-Thoms, C. R., Bottenus, N. B., Wangerin, K. A., Goldburgh, M. M., Tarbox, L., Beaucage‐Gauvreau, E., et al. (2024) · Medical Physics · doi:10.1002/mp.17442 · Cited by 19
Self-citationAdvancing in Silico Clinical Trials for Regulatory Adoption and Innovation
Karanasiou, G. S., Edelman, E. R., Boissel, F., Byrne, R. A., Emili, L., Fawdry, M., Filipović, N., Flynn, D., Geris, L., Hoekstra, A. G., et al. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3486538 · Cited by 21
“However, it should be highlighted that significant efforts have been made from both regulatory and industrial perspectives to advance this progress [134], [135], [136], [137].”
Challenges and opportunities in uncertainty quantification for healthcare and biological systems
Kimpton, L. M., Păun, L. M., Colebank, M. J., & Volodina, V. (2025) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2024.0232 · Cited by 30
“More resources are now dedicated towards modelling for medical device development [35], ‘patient-specific’ models [36] and in silico clinical trails [37].”
Fraser, A. G., Buccheri, S., Byrne, R. A., Kjærsgaard‐Andersen, P., James, S. K., Jüni, P., Bally, L., Bulbulia, R. A., Koletzko, B. V., Landray, M., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101460 · Cited by 15
“50 In silico ‘trials’ cannot be considered as a substitute for clinical investigations; they are approaches for estimating pre-clinical evidence and therefore out of scope for our report.”
Decoding uncertainty for clinical decision-making
Tsaneva-Atanasova, K. T., Pederzanil, G., & Laviola, M. (2025) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2024.0207 · Cited by 28
Qualification of mechanistic models in biopharmaceutical process development
Briskot, T., Hiltmann, D., Rischawy, F., Studts, J., & Kluters, S. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.11.021 · Cited by 6
Hammami, M., Yeddes, W., Gadhoumi, H., Yazidi, R., Tounsi, M. S., & Msaâda, K. (2025) · Xenobiotica · doi:10.1080/00498254.2025.2508804 · Cited by 7
“This aligns with the FDA’s push for computational tools in in silico trials (Pathmanathan et al. 2024).”
A Step‐by‐Step Workflow for Performing In Silico Clinical Trials With Nonlinear Mixed Effects Models
Cortés‐Ríos, J., Magee, M. H., Sher, A., Jusko, W. J., & Desikan, R. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70122 · Cited by 8
“This provides a comprehensive understanding of the model's ability to generate reliable predictions and its limitations [4, 46, 47].”
InfluentialRauseo, E., Bevis, L., Xu, C., et al. (2026) · European Heart Journal - Digital Health · doi:10.1093/ehjdh/ztag020 · Cited by 6
Effect of Humeral Stem Sizing and Alignment on Stress Shielding: A Virtual Cohort Study
Mueri, C., Maquer, G., Henderson, A., Bischoff, J. E., & Favre, P. (2025) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2025.3568877 · Cited by 5
“Finally, the current population based study used strain energy density in the cortical bone at time zero as a surrogate mapping model [48], [49] for the clinical outcome of cortical thinning, without explicitly modeling the longer term mechanical response, bone remodeling process or response in…”
de Vecchi, A., Cámara, Ó., Cavarra, R., del Álamo, J. C., El‐Bouri, W. K., Ferro, A., Lu, H. H.-S., Melidoro, P., Ogbomo-Harmitt, S., Olier, I., et al. (2026) · Thrombosis and Haemostasis · doi:10.1055/a-2761-5903 · Cited by 17
Hilhorst, P., van de Wouw, B., Zając, K., Veer, M. V. ’., Tonino, P. A. L., van de Vosse, F. N., & Huberts, W. (2025) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2024.0230 · Cited by 5
Cortés‐Ríos, J., Ren, T., Hanan, N., Sher, A., Nader, A., Magee, M. H., Jusko, W. J., & Desikan, R. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3718 · Cited by 5
“,8–11 Consequently, in silico trials and virtual experiments are now routinely and widely deployed across therapeutic areas including medical devices, 6 infectious diseases, 12–14 oncology, 15,16 vaccines, 17,18 immunology, 19–21 cardiology, 10 metabolic disorders, 22 and neurodegenerative diseases.”
In Silico Forensic Toxicology: Is It Feasible?
Šoša, I. (2025) · Toxics · doi:10.3390/toxics13090790 · Cited by 5
“…forensic toxicology progresses, the increased integration of computational tools into traditional lab methods is inevitable [34], requiring additional validation and a more seamless translation of complex simulation outcomes into legally relevant and straightforward expert opinions [11,35,36].”
Computational modeling and simulation for medical devices: a summary of the 2024 FDA/MDIC Symposium
Craven, B. A., Basciano, C. A., Afshari, P., et al. (2025) · Progress in Biomedical Engineering · doi:10.1088/2516-1091/ae1c05 · Cited by 4
“However, real-time clinical decision support is often reliant on fast running models, and in these cases, AI/ML could help to unleash the potential of CM&S. AI/ML also has potential to be used in ISCTs to map engineering quantities of interest from CM&S to clinical endpoints [8, 9].”
Self-citationRamella, A., Campo, G. D., Barati, S., Luraghi, G., Domanin, M., Fulgheri, I., Piffaretti, G., Heijmen, R. H., Migliavacca, F., & Trimarchi, S. (2026) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2026.01.008 · Cited by 4
Container applications for the development and integration of virtual imaging platforms
Barufaldi, B., Lago, M. A., Abadi, E., & Maidment, A. D. A. (2025) · Medical Physics · doi:10.1002/mp.17777 · Cited by 4
Virtual patient model for evaluating automated inspired oxygen control
Herrmann, J., Cruz, A. F., Varghese, F., LeCroy, D., Harvey, B. C., Giacometti, P., Lampe, J. W., Beck, G., Branson, R. D., & Kaczka, D. W. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110505 · Cited by 4
Langer, N., Escher, A., Öztürk, Ç., Stephens, A. F., Roche, E. T., Granegger, M., Kaye, D. M., & Gregory, S. D. (2025) · Annals of Biomedical Engineering · doi:10.1007/s10439-025-03821-z · Cited by 2
“AI-driven virtual trials could allow researchers to conduct in silico trials that improve the design, development, testing, and monitoring of new medical devices, for example by optimizing anatomical fit [60] and evaluating hemodynamic responses in a virtual environment [61].”
Advancing neuroengineering with Neuromorphic Twins
Chiappalone, M., & Levi, T. (2026) · Nature Communications · doi:10.1038/s41467-026-68923-1 · Cited by 7
“Instead, they function as powerful predictive tools to simulate disease progression and treatment effects, possibly supporting in silico experimentation and virtual clinical trials 29,30 .”
Rauseo, E., Bevis, L., Chen, X., et al. (2026) · Frontiers in Digital Health · doi:10.3389/fdgth.2026.1832926 · Cited by 2
“Finally, the lack of standardised verification procedures and uncertainty reporting remains a barrier to model credibility and reproducibility across centres (88).”
Evangelia, P., Tzamaria, D., Liakou, C. I., et al. (2025) · IOSR Journal of Multidisciplinary Research · doi:10.9790/7439-0202020716 · Cited by 2
Roche, E. T., Singh, M., Mendez, K. L., Ayers, B. C., Wang, S. X., Takahashi, A., Teodorescu, D. L., Mill, J., Albors, C., Escher, A., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6283242/v1 · Cited by 2
An open source statistical web application for validation and analysis of virtual cohorts
Ohmann, C., Khorchani, T., Cracanel, A., Brüning, J., & Verde, P. E. (2025) · Scientific Reports · doi:10.1038/s41598-025-99720-3 · Cited by 1
“…that computational (in silico) modelling and simulation (M&S) are powerful tools that complement traditional methods for gathering evidence–including bench-top (in vitro) testing, and animal or clinical (in vivo) studies– about products regulated by FDA or for developing FDA policy 20,27,28 .”
Fischer, L., Thiel, J., Blum, C., et al. (2025) · ASAIO Journal · doi:10.1097/mat.0000000000002529 · Cited by 1
Kostelich, E. J., Xu, Y., Calderón-Valero, C. E., Harris, D. C., Alcantar-Garibay, O., Gomez-Castro, G., On, T. J., Dortch, R. D., Kuang, Y., & Preul, M. C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1647144 · Cited by 1
Coleman, J. A., Camps, J., Hasaballa, A. I., et al. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111222 · Cited by 1
“…should consider all sources of error and propagation in the inference process, of particular relevance in the context of arrhythmia simulations which may be sensitive to small errors in the inferred ventricular model (Corral-Acero et al., 2020; Niederer et al., 2020; Pathmanathan et al., 2024).”
Digital twins for cardiopulmonary medicine: the case for pulmonary arterial hypertension
Niederer, S., Balmus, M., Burr, C., Chico, T., Clayton, R. H., Bai, W., Rangel-Smith, C., Wagg, D., Wilkinson, R. D., Wang, S., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag082 · Cited by 2
Self-citationHe, X., Wang, X., Xiang, W., et al. (2026) · AEU - International Journal of Electronics and Communications · doi:10.1016/j.aeue.2026.156411 · Cited by 1
Agbo, C. E., Nwankwo, C. K., Onyehalu, J. C., Agu, M. C., Opah, C., & Nworu, C. S. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.104986 · Cited by 2
Методологія і практика конвергенції міждисциплінарних знань у сфері цифрової охорони здоров’я
Petrenko, M. G., & Malakhov, K. S. (2025) · Information Technologies and Systems (Інформаційні технології та системи) · doi:10.15407/intechsys.2025.03.076 · Cited by 2
Andreassen, T. E., Trentadue, T. P., Thoreson, A. R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.17.705556 · Cited by 1
“The growing importance of personalized medicine 3 , along with recent trends in digital twins 4-6 and in silico clinical trials 7 , has led to an increased prominence of these models in clinical-translational orthopaedics to predict surgical outcomes 8 , evaluate new joint arthroplasty component…”
Gupta, A., Segars, L., Singletary, D. A., Hansen, J. L., Geale, K., Arora, A., Gomes, M., Ramagopalan, S. V., Cheung, W. Y., & Arora, P. (2024) · medRxiv · doi:10.1101/2024.09.10.24313417
Striking the balance: Complexity, simplicity, and credibility in mathematical biology
Rodero, C., & Niederer, S. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2504067122
Self-citationBobis, G., Tzamaria, D., Liakou, C. I., -, E. P., Papadakis, M., & Plytas, M. (2025) · International Journal of Engineering Technologies and Management Research · doi:10.29121/ijetmr.v12.i4.2025.1569
Goubergrits, L., Yevtushenko, P., Schlief, A., et al. (2025) · International Journal for Numerical Methods in Biomedical Engineering · doi:10.1002/cnm.70050
Manchel, A., Erdemir, A., Mulugeta, L., Ku, J. P., Rego, B. V., Horner, M., Lytton, W. W., Myers, J. G., & Vadigepalli, R. (2025) · PLoS ONE · doi:10.1371/journal.pone.0313711
Liew, A. C., Strocchi, M., Rodero, C., Gillette, K. K., Wijesuriya, N., Howell, S., de Vere, F., Vigmond, E. J., Plank, G., Niederer, S., et al. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1644520
“A His-Purkinje network was added to each heart geometry based on previous studies (Gillette et al., 2021; 2022; Pathmanathan et al., 2024), as described in the Supplementary Material.”
Self-citationLeung, G. H. D., Pun, F. W., Naumov, V., Gennert, D. G., Kamya, P. R. N., Aliper, A., Ren, F., & Zhavoronkov, A. A. (2026) · Springer eBooks · doi:10.1007/978-3-031-98022-0_3 · Cited by 1
Donker, D. W., & Fresiello, L. (2026) · Perfusion · doi:10.1177/02676591261424661
“53 It is evident that, to support medical devices, a model must demonstrate credibility, namely, by producing reliable predictions, especially as development progresses from design to preclinical and clinical testing.”
Solís-Lemus, J. A., Barrows, R. K., Rodero, C., Strocchi, M., Montarello, N., Lahoti, N., Corrado, C., Qayyum, A., Rahmani, S., Roney, C. H., et al. (2026) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1014325 · Cited by 1
“However, full validation for in silico clinical trials would require additional hierarchical evaluation steps, including patient-specific functional validation, uncertainty quantification, and context-specific device or drug interaction studies [67].”
Self-citationHorner, M., & Nagaraja, S. (2026) · Springer eBooks · doi:10.1007/978-3-032-09180-2_6
Verification, Validation and Uncertainty Quantification of Cardiac Electrophysiological Models
Pathmanathan, P. (2026) · Springer eBooks · doi:10.1007/978-3-032-09180-2_19
Self-citationda Silva-Filho, J. E., & Filho, E. D. G. (2026) · International Endodontic Journal · doi:10.1111/iej.70233
Galiana-Bordera, A., Aquerreta-Escribano, J., Martínez-Gironés, P. M., Lozano, P., Ribas, G., Jimenez-Gomez, P., Segrelles, J. D., Alberich, L. C., Blanquer, I., & Martí‐Bonmatí, L. (2026) · European Radiology Experimental · doi:10.1186/s41747-026-00770-7
The skeletal connectome: From molecular circuitry to systemic network medicine
Liu, W., Liu, D., Liu, Q., & Sun, Y. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100154
Adverse event reporting and regulatory analysis of pediatric cardiac assist devices
Ding, S., Wunnava, S., Liu, G., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0355401
“The FDA’s own Center for Devices and Radiological Health has published a formal credibility-assessment workflow for in silico clinical trials of medical devices, explicitly intended to support regulatory evaluation of device safety and effectiveness using computational models of patients [42].”
Ensuring the quality of in silico evidence: application to medical devices
Horner, M., Amar, A., Frangi, A. F., Maluf-Burgman, M. D. C., Marchal, T., & Pappalardo, F. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag442
“Articles from the peer-reviewed literature also highlight the importance of this connection [ 30, 31].”
Computational Nutrition 2.0: an algorithmic frontier for AI agents
Xie, M., Shen, C., Zhu, R., & Lv, C. (2026) · AI Agent · doi:10.20517/aiagent.2026.32
In silico methodologies in computational medicine: From complex disease modeling to virtual clinics
Italia, M., Otero, J. G., Azzimonti, L., García‐Aznar, J. M., Dercole, F., & Belmonte-Beitia, J. (2026) · Biophysics Reviews · doi:10.1063/5.0285118
Xie, M., Dong, Y., Guo, J., He, J., Wang, R., Martinez, J. A., & Zhu, R. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101852
Balmus, M., Wang, S., Ashton, E. W. G., Barrows, R. K., Monks, M., Ge, Y., Lefebvre, A. L., & Niederer, S. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70492 · Cited by 1
“We retain the term ISCT, which is established across the literature this review is aiming to consolidate, 8,14–15 noting that the use of alternative terminology would further fragment the terminology.”
Self-citationStructural and Combinatorial Design Principles of Emerging Drug Carriers
Kantorow, J., & Chakraborty, S. (2026) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.6c00095
Risk-informed framework for in silico regulatory evaluation of medical devices
Xue, Y., Sarrami‐Foroushani, A., Kreuzer, S. M., McVeigh, C., Grumbridge, M., Bombien, R., McLaren, A., Pandey, P. K., Ademiloye, A. S., Tyler, P., et al. (2026) · Device · doi:10.1016/j.device.2026.101303
Metadata
- Authors
- Pathmanathan, P., Aycock, K., Badal, A., Bighamian, R., Bodner, J., Craven, B. A., & Niederer, S.
- Affiliations
- United States Food and Drug Administration (US)
- Medtronic (United States) (US)
- The Alan Turing Institute (GB)
- Corresponding author
- Pathmanathan, Pras
- ORCID
- Venue
- PLOS Computational Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2024-08-08
- Volume
- 20
- Issue
- 8
- Pages
- e1012289
- ISSN
- 1553-734X (ISSN-L)
- 1553-7358
- PMC
- PMC11309390
- OpenAlex
- W4401418803
- Cited by
- 62
- References
- 70
- Citations by year
- 2026: 30 · 2025: 27 · 2024: 5
- FWCI
- 21.28
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- creativecommons.org/publicdomain/zero/1.0/ (vor)
- Locations
- PLoS Computational Biology (publishedVersion, public-domain)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
- Social Sciences › Education › Simulation-Based Education in Healthcare
- Keywords
- in silico clinical trials, medical devices, credibility assessment, model verification and validation, uncertainty quantification, patient modeling, virtual patients, subject-specific modeling, standardization
- MeSH terms
- Clinical Trials as Topic, Computer Simulation, Equipment and Supplies, Reproducibility of Results
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.